Skip to Main Content

Paper Details

Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma.
Clin Genitourin Cancer
6
2022
FGFR3, Infigratinib, LOT, Metastatic Urothelial Carcinoma, PATIENTS, Patients, bladder primary tumor, fibroblast growth factor receptor (FGFR) 1-3, infigratinib, mUC, metastatic urothelial cancer, patients, platinum, tyrosine, tyrosine kinase, upper tract urothelial carcinoma
Author NameAffiliation
David I QuinnUSC Norris Comprehensive Cancer Center
Matthew D GalskyMount Sinai School of Medicine
  • 1 - 2

Datasets

Release 1.2